Linvoseltamab
Regeneron
['mmsm']
 early, deep, and durable responses were observed in patients who were mostly triple refractory, said lead investigator hans c. lee, md. #mmsm #asco23 | 
Home of the journal ONCOLOGY®, CancerNetwork® offers different perspectives on oncology/hematology through review articles, news, podcasts, blogs, and more.